BACKGROUND/AIMS: To determine breast cancer metastasis suppressor 1 (BRMS1) expression in breast cancers and the efficacy of BRMS1 as a prognostic indicator, BRMS1 expression was assessed in two sets of breast cancer tissues. METHODS: Epithelial cells from 36 frozen samples of breast cancers and corresponding normal breast were collected by laser capture microdissection and assessed for BRMS1 by quantitative RT-PCR and immunohistochemistry. BRMS1 was also evaluated by immunohistochemistry in a tissue microarray of 209 breast cancers and correlated with indicators of prognosis [estrogen receptor (ER), progesterone receptor (PR), ErbB2, p53, p27(Kip1), Bcl2 and Ki-67]. RESULTS: BRMS1 mRNA and protein were higher in 94 and 81%, respectively, of breast cancers than in corresponding normal epithelium. BRMS1 localization was predominantly nuclear, but 60-70% of cancers also exhibited cytoplasmic immunostaining. Breast cancers with lower nuclear than cytoplasmic BRMS1 (nuclear score - cytoplasmic score < or =0; 11% of cancers) had lower ER, lower PR and higher Ki-67 expression. There was also a trend toward poorer overall survival in this group of cancers, but this was only of borderline significance (p = 0.073). In Cox proportional hazards models, loss of nuclear BRMS1 was not a significant predictor of overall survival. CONCLUSIONS: Loss of nuclear BRMS1 was associated with ER-negative cancers and a high rate of proliferation, but was not an independent indicator of prognosis. Copyright 2009 S. Karger AG, Basel.
BACKGROUND/AIMS: To determine breast cancer metastasis suppressor 1 (BRMS1) expression in breast cancers and the efficacy of BRMS1 as a prognostic indicator, BRMS1 expression was assessed in two sets of breast cancer tissues. METHODS: Epithelial cells from 36 frozen samples of breast cancers and corresponding normal breast were collected by laser capture microdissection and assessed for BRMS1 by quantitative RT-PCR and immunohistochemistry. BRMS1 was also evaluated by immunohistochemistry in a tissue microarray of 209 breast cancers and correlated with indicators of prognosis [estrogen receptor (ER), progesterone receptor (PR), ErbB2, p53, p27(Kip1), Bcl2 and Ki-67]. RESULTS:BRMS1 mRNA and protein were higher in 94 and 81%, respectively, of breast cancers than in corresponding normal epithelium. BRMS1 localization was predominantly nuclear, but 60-70% of cancers also exhibited cytoplasmic immunostaining. Breast cancers with lower nuclear than cytoplasmic BRMS1 (nuclear score - cytoplasmic score < or =0; 11% of cancers) had lower ER, lower PR and higher Ki-67 expression. There was also a trend toward poorer overall survival in this group of cancers, but this was only of borderline significance (p = 0.073). In Cox proportional hazards models, loss of nuclear BRMS1 was not a significant predictor of overall survival. CONCLUSIONS: Loss of nuclear BRMS1 was associated with ER-negative cancers and a high rate of proliferation, but was not an independent indicator of prognosis. Copyright 2009 S. Karger AG, Basel.
Authors: Douglas R Hurst; Alka Mehta; Blake P Moore; Pushkar A Phadke; William J Meehan; Mary Ann Accavitti; Lalita A Shevde; James E Hopper; Yi Xie; Danny R Welch; Rajeev S Samant Journal: Biochem Biophys Res Commun Date: 2006-08-10 Impact factor: 3.575
Authors: Louise M Kelly; Yvonne Buggy; Arnold Hill; Norma O'Donovan; Catherine Duggan; Enda W McDermott; Niall J O'Higgins; Leonie Young; Michael J Duffy Journal: Tumour Biol Date: 2005-07-06
Authors: Lalita A Shevde; Rajeev S Samant; Jason C Paik; Brandon J Metge; Ann F Chambers; Graham Casey; Andra R Frost; Danny R Welch Journal: Clin Exp Metastasis Date: 2006-07-09 Impact factor: 5.150
Authors: Shoichiro Ohta; Edwin W Lai; Alan L Y Pang; Frederieke M Brouwers; Wai-Yee Chan; Graeme Eisenhofer; Ronald de Krijger; Lucia Ksinantova; Jan Breza; Pavel Blazicek; Richard Kvetnansky; Robert A Wesley; Karel Pacak Journal: Int J Cancer Date: 2005-03-10 Impact factor: 7.396
Authors: Daryll B DeWald; Javad Torabinejad; Rajeev S Samant; Derrick Johnston; Nuray Erin; Joseph C Shope; Yi Xie; Danny R Welch Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701
Authors: Lydia Nakopoulou; Eleni Mylona; Ioanna Papadaki; N Kavantzas; I Giannopoulou; S Markaki; A Keramopoulos Journal: Mod Pathol Date: 2006-04 Impact factor: 7.842
Authors: N Kaushik; D Fear; S C M Richards; C R McDermott; E F Nuwaysir; P Kellam; T J Harrison; R J Wilkinson; D A J Tyrrell; S T Holgate; J R Kerr Journal: J Clin Pathol Date: 2005-08 Impact factor: 3.411
Authors: Yekaterina B Khotskaya; Benjamin H Beck; Douglas R Hurst; Zhenbo Han; Weiya Xia; Mien-Chie Hung; Danny R Welch Journal: Mol Carcinog Date: 2013-09-02 Impact factor: 4.784
Authors: Leah M Cook; Xuemei Cao; Alexander E Dowell; Michael T Debies; Mick D Edmonds; Benjamin H Beck; Robert A Kesterson; Renee A Desmond; Andra R Frost; Douglas R Hurst; Danny R Welch Journal: Clin Exp Metastasis Date: 2012-01-13 Impact factor: 5.150
Authors: Yuan Liu; Elianna B Amin; Marty W Mayo; Neel P Chudgar; Peter R Bucciarelli; Kyuichi Kadota; Prasad S Adusumilli; David R Jones Journal: Cancer Res Date: 2016-03-15 Impact factor: 12.701